< Back to Article

Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia

Fig 3

Results from regression discontinuity analyses on the effects of expanding treatment eligibility to patients with CD4 between 350 and 500 cells/μL and pregnant/breastfeeding women on ART initiation at 3 months, retention in care at 6 months, and the percentage of patients in care and on ART at 6 months.

Fig 3